Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
Clinical trial NCT02910063 · COMPLETED
Trial details
- NCT number
- NCT02910063
- Sponsor
- Amgen
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-01-23
- Primary completion
- 2020-03-12
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.